Jenkem Technology (688356.SH): The first subject to be enrolled in the Phase II clinical study of JK1201I for the treatment of triple-negative breast cancer with brain metastases has been completed.

Jenkem Technology (688356.SH) announced that the phase II clinical trial "JK1201I treatment for triple-negative breast cancer with brain metastasis" has recently enrolled its first participant. JK1201I is a small-molecule long-acting anti-cancer type 1 innovative drug independently developed by the company. The drug, a novel chemical compound modified with polyethylene glycol, has shown better efficacy and safety compared to commercially available erlotinib in preclinical studies. The drug obtained clinical trial approval in January 2016 and the results of the completed phase II clinical trial "Safety, tolerability, and preliminary efficacy study of JK1201I in patients with small cell lung cancer" showed good safety, tolerability, and a tendency to extend patient survival, indicating that it may benefit patients in treatment.